Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT in Refractory Sarcoidosis
NCT00282438Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Dec 2003
- Primary completion
- Aug 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous hematopoietic stem cells in sarcoidosis (2 arms), sponsored by Northwestern University. Primary endpoints: Presence of Toxicity, Survival at 5 years and 1 more. Started Dec 2003; status: terminated.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT00282438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282438.